

Review

Cost-Effectiveness of Telemedicine vs Standard Care for the Management of Diabetes Mellitus, Hypertension, and Heart Failure: Meta-Analysis of Randomized Trials

Cecilia Acuti Martellucci^{1*}, MD, MSc; Natalia Gregori^{1*}, MD; Sara Taormina¹, MD; Igor Diemberger¹, MD, DHS; Barbara Sena², BA, DSocSci; Gaia Matilde Ripamonti³, BA, DSocSci; Camillo Odio⁴, BEng; Maria Elena Flacco⁵, MD; Asher Daniel Colombo⁶, BA, DSocSci; Salvatore Vassallo^{7,8}, BA, DSocSci; Lamberto Manzoli^{1,5}, MD, MPH

¹Department of Medical and Surgical Sciences, University of Bologna, Bologna, Emilia-Romagna, Italy

²Department of Letters, Philosophy, Communication, University of Bergamo, Bergamo, Lombardy, Italy

³Department of Political and Social Sciences, University of Trieste, Trieste, Italy

⁴Healthcare Department, Abruzzo Region, Pescara, Italy

⁵Department of Environmental and Prevention Sciences, University of Ferrara, Ferrara, Emilia-Romagna, Italy

⁶Department of Political and Social Sciences, University of Bologna, Bologna, Emilia-Romagna, Italy

⁷Carlo Cattaneo Institute Research Foundation, Bologna, Italy

⁸Department of The Arts, University of Bologna, Bologna, Emilia-Romagna, Italy

*these authors contributed equally

Corresponding Author:

Lamberto Manzoli, MD, MPH

Department of Medical and Surgical Sciences

University of Bologna

Via San Giacomo 12

Bologna, Emilia-Romagna 40126

Italy

Phone: 39 3474727282

Email: lamberto.manzoli2@unibo.it

Abstract

Background: The effectiveness of telemedicine strategies for the efficient management of chronic diseases has been evaluated in a number of studies, and the most recent umbrella review of meta-analyses on the topic concluded that there is sufficient evidence supporting the use of telehealth for patients with diabetes, hypertension, and heart failure. However, in-depth assessments of the cost-effectiveness of telemedicine are severely lacking.

Objective: This meta-analysis aimed at estimating the incremental cost-effectiveness ratios (ICERs) of telemedicine for the management of type 2 diabetes mellitus, hypertension, and heart failure.

Methods: We searched MEDLINE, Scopus, ClinicalTrials.gov, and the Tufts Medical Center Cost-Effectiveness Analysis Registry for all randomized or quasi-randomized trials that evaluated the cost-effectiveness of telemedicine vs standard care for managing the selected diseases. The outcomes were the ICER per quality-adjusted life year (QALY) gained, a reduction in systolic blood pressure of 1 mm Hg, or a reduction in hemoglobin A_{1c} of 1% after 12 months of follow-up. Random-effects meta-analyses were run when sufficient data were provided, and weighted ICER means were computed.

Results: A total of 27 trials were included in this meta-analysis (with a total of 15,658 patients): 40.7% (n=11) on hypertension, all using telemonitoring; 22.2% (n=6) on heart failure; and 37% (n=10) on diabetes, mostly using telephone support. Meta-analyses were possible for only two outcomes, as most trials did not report a measure of dispersion: (1) the summary estimate of ICER per QALY gained among patients with heart failure based on 11.1% (n=3) of the trials (1825 patients) was US \$45,741 ($P=.24$), whereas the weighted mean based on 18.5% (n=5) of the trials (3288 patients) was US \$40,271 (SD 22,933) and (2) the summary estimate of ICER per systolic blood pressure reduction of 1 mm Hg based on 18.5% (n=5) of the studies (1986 patients) was US \$27, whereas the weighted mean was US \$132 (SD 227) based on 33.3% (n=9) of the trials (3450 patients). The weighted means of ICER per QALY gained for hypertension and diabetes were US \$18,966 (SD 13,286; n=3, 11.1% of the studies and 1437 patients) and US \$44,725 (SD 18,925; n=5, 18.5% of the studies and 2949 patients),

respectively. Finally, the weighted mean of ICER per 1% hemoglobin A_{1c} reduction was US \$3349 (SD 2249; n=7, 25.9% of the studies and 4157 patients). Some of the estimates were substantially lower when only recent trials were considered.

Conclusions: The results support using telemedicine as a cost-effective strategy to monitor hypertension, heart failure, and, depending on the willingness to pay, diabetes. Further randomized controlled trials reporting CIs for ICER are required to confirm these findings.

J Med Internet Res 2026;28:e95367; doi: [10.2196/95367](https://doi.org/10.2196/95367)

Keywords: telemedicine; diabetes mellitus; hypertension; heart failure; cost-effectiveness; incremental cost-effectiveness ratio; ICER; telemonitoring; meta-analysis

Introduction

According to World Health Organization data from years 2000 to 2021, chronic conditions—diabetes, Alzheimer disease, and other noncommunicable diseases—caused growing morbidity and mortality worldwide [1]. The resulting productivity losses and health care use have a significant impact on health care financing [2], as outlined by a 2025 report that estimated the average expenditure for noncommunicable diseases across Organisation for Economic Co-operation and Development countries at US \$207 million per 100,000 population [3].

In an effort to identify more efficient service delivery models, the main solutions that have been proposed are the enhancement of prevention services [4,5]; the addition of intermediate care [6,7]; and the introduction of telemedicine (or telehealth), which has rapidly expanded since the 1990s [8,9]. In particular, in the United States, the adoption of telehealth services peaked in 2020 with the COVID-19 pandemic, and although their use has since declined, they remain above prepandemic levels in both urban and rural settings [10].

Specifically, the effectiveness of telemedicine strategies for the management of chronic diseases has been evaluated in a number of studies [11,12], and the most recent umbrella review of meta-analyses on the topic concluded that there is sufficient evidence supporting the use of telehealth for patients with diabetes, hypertension, and heart failure [13]. However, the authors called for an in-depth assessment of the cost-effectiveness of telemedicine and joined several previous reports in criticizing the lack of homogeneity across cost evaluations in the field [14-17]. In addition, cost-effectiveness analyses are further complicated by the great variety of organizational models and technological solutions used in telemedicine, often producing contrasting results [18,19].

By quantitatively synthesizing the available evidence on cost-effectiveness in this field, the present study sought to provide a more comprehensive assessment of the economic value of telemedicine interventions across 3 major chronic diseases. To this end, we carried out a meta-analysis of randomized controlled trials (RCTs) aimed at estimating the incremental cost-effectiveness ratios (ICERs) of telemedicine vs standard care for the management of diabetes, hypertension, and heart failure.

Methods

Search Strategy, Selection Criteria, and Methodological Quality

We searched MEDLINE, Scopus, ClinicalTrials.gov, and the Tufts Medical Center Cost-Effectiveness Analysis Registry for randomized or quasi-randomized clinical trials that used their data to evaluate the cost-effectiveness of telemedicine vs standard care for the management of type 2 diabetes mellitus, hypertension, and heart failure. The meta-analysis was limited to these 3 diseases as they all represent chronic cardiovascular conditions that are measurable through standardized tests and characterized by similar long-term care requirements and for which both cost-effectiveness evaluations and telemedicine interventions are well established in the literature, with RCTs dating back to before 2005 [20,21]. Indeed, several telemedicine trials conducted throughout the years have enrolled patients with multiple chronic diseases or risk factors, most often diabetes, hypertension, and heart failure [22-24], and suggest that telehealth could be efficacious in controlling these conditions [13]. To be included in this study, trials had to estimate the ICER per quality-adjusted life year (QALY) gained or the ICER per another primary outcome (1% reduction in hemoglobin A_{1c} [HbA_{1c}] for diabetes and 1-mm Hg reduction in systolic blood pressure [SBP] for hypertension) using a follow-up equal to or longer than 3 months [16].

Further details on the identification and selection processes are reported in [Multimedia Appendix 1](#) [24-30].

Outcomes and Data Analysis

The primary outcome was the ICER per QALY gained, which is considered a foundational metric to evaluate the value of a health intervention and allows for cross-disease comparisons of health benefits by quantifying gains in both duration and quality of life [31,32]. The ICER was defined as the difference in costs divided by the difference in QALYs between telemedicine and standard care [33], indicating telemedicine cost per additional QALY gained. Secondary outcomes were ICER per 1% reduction in HbA_{1c} and ICER per 1-mm Hg reduction in SBP.

When available, we extracted the 95% CIs or uncertainty intervals, computed the SE of the ICER, and computed a summary estimate of the mean difference in ICER across individual studies using a random-effects [34] generic inverse variance approach to account for between-study heterogeneity

[35]. This approach was adopted as it is cited in the literature among those appropriate for meta-analyzing ICERs [36]. All costs were adjusted to 2025 USD, and between-study heterogeneity was quantified using the I^2 metric. Specifically, as inflation adjustment was reportedly performed in most (>80%) of the included studies, the current conversion simply aimed to adjust for the inflation that occurred between the time of publication and the year 2025 using the US consumer price index. Inflation adjustment was performed after currency conversion as practically all studies were conducted in high-income countries and the US inflation rate was considered sufficiently representative of all the study settings [37].

Meta-analysis was performed by pooling only studies with results in the same quadrant of the cost-effectiveness plane (ie, when ICERs indicated that the telemedicine intervention had a higher efficacy for an increased cost compared to control [36]). When most trials did not report an estimate of ICER SE, P value, or CIs, missing data imputation was inappropriate, and head-to-head meta-analysis could not be performed [38]. The health economic findings were synthesized narratively and presented using tables and graphics [2] in which the weighted mean of the ICER was shown. ICER means were weighted for the sample size, separately reported for each outcome, disease, and date of publication (excluding studies published before 2015). Given the variability in follow-up length of the included studies, in an attempt to reduce individual study variability, the estimates of the RCTs that used different follow-ups were recomputed assuming (1) constant effectiveness over time and (2) linear increase in costs with time (eg, the ICER of a trial with a 6-month follow-up was doubled). A 12-month follow-up was commonly assumed to be a sufficient time frame to detect meaningful changes in disease control from a clinical and organizational point of view. While this approach may overestimate the interventions' setup costs, it was selected over more complex modeling approaches to simplify the interpretation of the results given that most of the included studies (14/27, 51.9%) used a 12-month follow-up. As no meta-analysis included more than 7 trials, potential publication bias could not be assessed through formal testing of funnel plot asymmetry [39].

All meta-analyses were carried out using RevMan (version 5.4; The Cochrane Collaboration).

Results

Study Selection and Characteristics


The PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram of the selection

process is summarized in [Figure 1](#) [25]. Of the 4183 papers initially retrieved, a total of 27 (0.6%) RCTs used trial data to estimate and report one of the selected outcomes and were included in the meta-analyses.

The main study characteristics are reported in [Multimedia Appendix 2](#) [40-65] stratified by disease: diabetes (10/27, 37% of the RCTs) [40-49], hypertension (11/27, 40.7% of the RCTs) [50-60], and heart failure (6/27, 22.2% of the RCTs) [58,61-65]. The first trial was published in 2005; 55.6% (15/27) of the studies were published after 2015 and were defined as “more recent.” In total, 29.6% (8/27) of the RCTs were carried out in the United States; 18.5% (5/27) were carried out in the United Kingdom; 25.9% (7/27) were carried out in other European countries; and the remaining studies (7/27, 25.9%) were carried out in Australia, Bangladesh, Brazil, Russia, and Singapore. The sample sizes ranged from 117 to 1665 (564 on average, SD 444), and the duration of follow-up ranged from 3 to 60 months, although most of the trials (14/27, 51.9%) followed patients for 12 months. Almost all RCTs computed ICERs from the health care provider (13/27, 48.1%) or health care system (13/27, 48.1%) perspective; the interventions included telemonitoring in all trials on hypertension management (11/11, 100%), whereas most studies on diabetes and heart failure used some form of telephone coaching or support. Interestingly, 40.7% (11/27) of the studies did not report a willingness-to-pay (WTP) threshold, and among the studies providing a WTP threshold for QALYs, this was highly variable: from US \$5000 to US \$100,000. Only 7.4% (2/27) of the studies cited a threshold for 1-mm Hg reductions in SBP (US \$27 to US \$4071) [52, 57], and 3.7% (1/27) of the studies cited a threshold for 1% reductions in HbA_{1c} (US \$1000) [40].

The methodological quality of the included RCTs is reported in [Multimedia Appendix 3](#) [40-65]. Most RCTs (25/27, 92.6%) had an intermediate risk of bias, and only 7.4% (2/27) were judged to have a high risk of bias. The most common sources of concern were inadequate or insufficiently described methods to handle missing data (21/27, 77.8% of the RCTs), handle deviations from the intended interventions (20/27, 74.1%), and measure outcomes (17/27, 63%). The randomization process and the selection of the reported results were less concerning, especially in view of the wide standardization of outcomes for diabetes (HbA_{1c}) and hypertension (SBP).

Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram [25]. CEA: Tufts Medical Center Cost-Effectiveness Analysis Registry; ICER: incremental cost-effectiveness ratio.



Primary Outcome: ICER per QALY Gained

In total, 48.1% (13/27) of the RCTs estimated the ICER per QALY gained (Multimedia Appendix 2), but only 3 of the trials on heart failure management reported sufficient data (95% CI, *P* value, or SE) to be included in the meta-analysis. Overall, based on a total sample of 1825 patients, the summary estimate of ICER per QALY gained of telemedicine vs standard care on a 12-month follow-up was US \$45,741, with a large, nonsignificant 95% CI (–US \$31,050 to US \$122,533; *P*=.24). In the more recent RCT by González-Guerrero et al [65], the telehealth intervention was more effective and cost-saving compared to standard care.

The weighted means of the 48.1% (13/27) of the studies reporting the ICER per QALY gained are reported in Multimedia Appendix 4 [42,43,45,48,49,57–59,61–64]. The average ICER largely varied by disease, being highest for the management of diabetes (5/13, 38.5% of the studies, 2949 patients; US \$44,725, SD 18,925), intermediate for heart failure (5/13, 38.5% of the trials, 3171 patients; US \$40,271, SD 22,933), and lowest for hypertension (3/13, 23.1% of the studies, 1314 patients; US \$18,966, SD 13,289).

Secondary Outcomes: ICER per 1-mm Hg SBP Reduction and ICER per 1% HbA_{1c} Reduction


One out of the 11 hypertension trials did not calculate an ICER as higher effectiveness was found in the control arm; therefore, it could not be used for either SBP reductions or QALY gained [60]. In total, 90% (9/10) of the studies on hypertension computed the ICER per 1-mm Hg SBP reduction, and 70% (7/10) of the RCTs on diabetes reported an ICER per 1% HbA_{1c} decrease. However, only 50% (5/10) of the trials on hypertension, including a total of 1986 patients, reported sufficient data and were included in a meta-analysis (Figure 2). Overall, the summary estimate of ICER per 1-mm Hg reduction in SBP of telemedicine vs standard care for a 12-month follow-up was US \$27 (95% CI US \$6.4–\$47.7; *P*=.01). The weighted mean for the same outcome from the 90% (9/10) of the trials on hypertension that reported an ICER was US \$132 (SD 227; [50–57,59] Multimedia Appendix 4).

With regard to the ICER per 1% HbA_{1c} reduction, no meta-analyses were possible as no trial reported a measure of dispersion from the mean, and the weighted mean of the

7 trials that reported an ICER, including a total of 4157 patients, was US \$3349 (SD 2249; [Multimedia Appendix 4](#) [40,41,43-46,48]). When only the 2 more recent trials were

considered, the average ICER decreased to US \$1629 (SD 743).

Figure 2. Random-effect meta-analysis of randomized controlled trials (RCTs) evaluating the cost-effectiveness of telemedicine versus standard care for blood pressure management: incremental cost-effectiveness ratio (ICER) needed to achieve a 1 mm Hg reduction in systolic blood pressure. In this generic inverse variance model, only RCTs that reported the SD or CIs could be included in the meta-analysis [50-52,55,56].



Discussion

The main findings from our review are the following: (1) after more than 20 years of implementation, the available evidence based on high-quality, randomized data is still limited, as only 27 studies (with a total of 15,658 patients) estimated an ICER for 3 of the most common diseases in the world [66]; (b) in addition to some expected and somewhat inevitable heterogeneity due to the model of care or intervention, 48.1% ($n=13$) of the trials did not report any data to derive CIs for any outcome, which further limited the possibility to run the meta-analyses and their validity; and (3) from the available trials, our analysis suggests that implementing telemedicine strategies was cost-effective, with large variations across diseases: the lowest weighted mean ICER per QALY gained for the adoption of telehealth for 12 months as compared to usual care was found in hypertension (US \$18,966), followed by heart failure (US \$40,271) and diabetes (US \$44,725), and the summary ICER per 1-mm Hg SBP reduction was also the lowest at US \$27.

An increasing body of evidence shows that telemedicine strategies for the management of chronic diseases may be similarly effective compared to usual care [26,67,68], and it is now crucial to obtain some reliable estimates on the cost-effectiveness that digital health services may offer in comparison to usual care [69]. The available evidence on the cost-effectiveness of telemedicine is highly heterogeneous and often comes from theoretical models with no primary data, and even the results of individual RCTs are complex to interpret by examining single trials. Although some systematic reviews have been previously published [2,70,71], the authors have reported the results narratively, and to our knowledge, this is the first quantitative meta-analysis of the cost-effectiveness of telemedicine vs standard care for the management of diabetes mellitus, hypertension, and heart failure.

Our findings are consistent with those of previous systematic reviews [2,12] describing remote patient monitoring-based tools as highly cost-effective interventions in hypertension and cardiovascular disease management. Another systematic review already demonstrated the potentiality of at-home blood pressure self-monitoring to be cost-effective over usual care, particularly in the long term [72]. However, as mentioned, this is the first study to summarize the results of previous studies using meta-analysis to evaluate the cost-effectiveness of telehealth solutions in both heart failure and hypertension.

With regard to diabetes management, no formal meta-analysis was possible as none of the RCTs included a measure of dispersion from the mean. However, the weighted mean of ICER per 1% HbA_{1c} reduction from the 5 trials that reported an ICER was US \$3349, which decreased to US \$1629 when considering only the 2 more recent trials [41,43]. Although these values are less favorable than those observed for hypertension and heart failure, they are nevertheless encouraging and should serve as a starting point for decision-makers and researchers. Especially for diabetes, but also for hypertension and heart failure, further economic evaluations from randomized trials are clearly, strongly needed, possibly using higher-quality reporting standards [73].

With regard to the policy implications of our findings, they inevitably vary depending on the national contexts considered as decision-makers compare the ICER to a WTP threshold: if the ICER is below that threshold, the treatment is deemed cost-effective. Most studies consider a WTP threshold per QALY between US \$30,000 and US \$50,000 as acceptable from the health system perspective [2]. Similarly, in the United Kingdom, the National Institute for Health and Care Excellence has traditionally used a threshold of £20,000 to £30,000 per QALY (£1=US \$1.35 as of July 17, 2026) [74]. Differently, in the United States, there is no single official threshold, but a WTP per QALY at around US \$50,000 to US \$150,000 is informally used by analysts [75]. This

variability from one context to another can make it challenging to establish cost-effectiveness worldwide because each local context requires its policymakers to determine whether the cost of interventions is worthwhile. Acknowledging this variability, the estimates provided in this analysis can be used as a starting point in planning health care policies worldwide. Further in-depth research is needed to better define WTP per QALY thresholds for these telehealth solutions across different settings considering specific socioeconomic conditions, health priorities, and characteristics of each health care system. Further research should therefore be extended to low-income settings where evidence on the effectiveness and cost-effectiveness of telehealth services is lacking and where a significant percentage of people affected by chronic diseases such as diabetes live [73].

This study has some limitations that must be considered in interpreting the results. First, as mentioned, the available data are relatively scarce, and we could only compute a weighted mean for the ICER on diabetes management. Another example is the discrepancy between the US \$45,741 summary estimate and the US \$31,976 weighted mean of the ICER per QALY gained for heart failure. The summary estimate was based on only 3 trials and presented large CIs, to the point that cost-effectiveness could not be confirmed, whereas the weighted mean was based on all 5 eligible trials. Future cost-effectiveness analyses should include either SEs or CIs around the ICER to allow for their inclusion in subsequent

meta-analyses. Second, some of the trials (8/27, 30%) were carried out 15 years ago or more, and the costs of telemedicine may have relevantly changed, as suggested by the highly volatile WTP thresholds. Indeed, when the analyses were restricted to the most recent trials, we observed a marked improvement in the selected outcomes for both heart failure and hypertension, which may reflect the general decrease in the costs associated with telemonitoring and tele-support [56]. Given the limited number of trials, however, this finding requires confirmation from more recent studies. Third, almost all the RCTs included in this meta-analysis (26/27, 96%) computed ICERs from the health care provider or health care system perspective, and this perspective may fail to capture additional benefits of telemedicine, including potential time and cost savings for patients [73]. Fourth, due to the limited number of studies included in each subgroup, it was not possible to identify whether different technologies used to support telemedicine (eg, computer, SMS, or smartphone), the use of interactive or noninteractive technology, the addition of telemonitoring, or a combination of these factors led to improved results.

The results of the present meta-analysis support the use of telemedicine as a cost-effective strategy to monitor hypertension; heart failure; and, depending on the WTP, diabetes mellitus. More RCTs reporting CIs for the ICER are, however, required to confirm these findings.

Funding

The authors declared no financial support was received for this work.

Data Availability

The datasets generated or analyzed during this study are available from the corresponding author on reasonable request.

Conflicts of Interest

None declared.

Multimedia Appendix 1

Search strategy, selection criteria, and methodological quality.

[\[DOC File \(Microsoft Word File\), 28 KB-Multimedia Appendix 1\]](#)

Multimedia Appendix 2

Randomized controlled trials evaluating the cost-effectiveness of telemedicine vs standard care for the management of type 2 diabetes and hypertension that estimated an incremental cost-effectiveness ratio value per 1 clinical outcome.

[\[DOC File \(Microsoft Word File\), 169 KB-Multimedia Appendix 2\]](#)

Multimedia Appendix 3

Quality assessment of the included randomized controlled trials according to version 2 of the Cochrane risk-of-bias tool for randomized trials (Sterne et al [76]).

[\[DOC File \(Microsoft Word File\), 101 KB-Multimedia Appendix 3\]](#)

Multimedia Appendix 4

Incremental cost-effectiveness ratios of telemedicine versus standard care for type 2 diabetes, hypertension, and heart failure, evaluating quality-adjusted life years, blood pressure, and hemoglobin A_{1c} outcomes across randomized controlled trials.

[\[DOC File \(Microsoft Word File\), 327 KB-Multimedia Appendix 4\]](#)

Checklist 1

PRISMA checklist.

[\[PDF File \(Adobe File\), 300 KB-Checklist 1\]](#)

References

1. World health statistics 2025: monitoring health for the SDGs, Sustainable Development Goals. World Health Organization. 2025. URL: <https://iris.who.int/server/api/core/bitstreams/c992fbdc-11ef-43db-a478-7e7a195403ae/content> [Accessed 2026-07-18]
2. De Guzman KR, Snoswell CL, Taylor ML, Gray LC, Caffery LJ. Economic evaluations of remote patient monitoring for chronic disease: a systematic review. *Value Health*. Jun 2022;25(6):897-913. [doi: [10.1016/j.jval.2021.12.001](https://doi.org/10.1016/j.jval.2021.12.001)] [Medline: [35667780](https://pubmed.ncbi.nlm.nih.gov/35667780/)]
3. Grimshaw S, Bourke E, Blakely T. Estimates of non-communicable disease expenditure by disease phase, sex, and age group for all OECD countries. *Popul Health Metr*. Oct 8, 2025;23(1):53. [doi: [10.1186/s12963-025-00418-5](https://doi.org/10.1186/s12963-025-00418-5)] [Medline: [41063263](https://pubmed.ncbi.nlm.nih.gov/41063263/)]
4. Polanco B, Oña A, Gemperli A, Pacheco Barzallo D. Excess healthcare utilization and costs linked to chronic conditions: a comparative study of nine European countries. *Eur J Public Health*. Apr 1, 2025;35(2):216-227. [doi: [10.1093/eurpub/ckaf012](https://doi.org/10.1093/eurpub/ckaf012)] [Medline: [39933031](https://pubmed.ncbi.nlm.nih.gov/39933031/)]
5. Troisi G, Small R, Chestnov R, et al. The reported impact of non-communicable disease investment cases in 13 countries. *BMJ Glob Health*. Apr 10, 2024;9(4):e014784. [doi: [10.1136/bmjgh-2023-014784](https://doi.org/10.1136/bmjgh-2023-014784)] [Medline: [38599663](https://pubmed.ncbi.nlm.nih.gov/38599663/)]
6. Garåsen H, Windspoll R, Johnsen R. Intermediate care at a community hospital as an alternative to prolonged general hospital care for elderly patients: a randomised controlled trial. *BMC Public Health*. May 2, 2007;7:68. [doi: [10.1186/1471-2458-7-68](https://doi.org/10.1186/1471-2458-7-68)] [Medline: [17475006](https://pubmed.ncbi.nlm.nih.gov/17475006/)]
7. Colprim D, Martin R, Parer M, Prieto J, Espinosa L, Inzitari M. Direct admission to intermediate care for older adults with reactivated chronic diseases as an alternative to conventional hospitalization. *J Am Med Dir Assoc*. Apr 2013;14(4):300-302. [doi: [10.1016/j.jamda.2012.12.003](https://doi.org/10.1016/j.jamda.2012.12.003)] [Medline: [23294969](https://pubmed.ncbi.nlm.nih.gov/23294969/)]
8. Moore M. The evolution of telemedicine. *Future Gener Comput Syst*. Mar 1999;15(2):245-254. [doi: [10.1016/S0167-739X\(98\)00067-3](https://doi.org/10.1016/S0167-739X(98)00067-3)]
9. McIntosh E, Cairns J. A framework for the economic evaluation of telemedicine. *J Telemed Telecare*. 1997;3(3):132-139. [doi: [10.1258/1357633971931039](https://doi.org/10.1258/1357633971931039)] [Medline: [9489107](https://pubmed.ncbi.nlm.nih.gov/9489107/)]
10. Cengil AB, Eksioglu B, Eksioglu SD, Hayes C, Bogulski C, Ali M. Resource use patterns in US telehealth services: machine learning and clustering analysis across 4 specialties. *JMIR Med Inform*. May 7, 2026;14:e78030. [doi: [10.2196/78030](https://doi.org/10.2196/78030)] [Medline: [42096693](https://pubmed.ncbi.nlm.nih.gov/42096693/)]
11. Nalkar S, Chandak A. Telemedicine for specific populations: evaluating effectiveness and barriers in enhancing healthcare access and outcomes. *J Public Health (Berl)*. 2025. [doi: [10.1007/s10389-025-02625-8](https://doi.org/10.1007/s10389-025-02625-8)]
12. Zhang K, Chen Y, Wang P, et al. Impact of telemedicine on chronic disease patients: an overview of systematic reviews. *Intell Med*. Apr 2026;6(2):226-233. [doi: [10.1016/j.imed.2025.01.002](https://doi.org/10.1016/j.imed.2025.01.002)]
13. Laukka E, Jansson M, Suonnansalo P, et al. Effectiveness of interactive digital health services in non-communicable diseases: an umbrella review and evidence synthesis from 26 meta-analyses. *Int J Nurs Stud*. Feb 2026;174:105277. [doi: [10.1016/j.ijnurstu.2025.105277](https://doi.org/10.1016/j.ijnurstu.2025.105277)] [Medline: [41270451](https://pubmed.ncbi.nlm.nih.gov/41270451/)]
14. Ivanova J, Shah B, Foote C, Cummins MR. Assessing the costs and savings of telemedicine: insights from the consolidated framework for implementation research. *Digit Health*. 2025;11:20552076251314552. [doi: [10.1177/20552076251314552](https://doi.org/10.1177/20552076251314552)] [Medline: [39882018](https://pubmed.ncbi.nlm.nih.gov/39882018/)]
15. Bell-Aldeghi R, Gibrat B, Rapp T, et al. Determinants of the cost-effectiveness of telemedicine: systematic screening and quantitative analysis of the literature. *Telemed J E Health*. Jul 2023;29(7):1078-1087. [doi: [10.1089/tmj.2022.0161](https://doi.org/10.1089/tmj.2022.0161)] [Medline: [36493368](https://pubmed.ncbi.nlm.nih.gov/36493368/)]
16. Whitten PS, Mair FS, Haycox A, May CR, Williams TL, Hellmich S. Systematic review of cost effectiveness studies of telemedicine interventions. *BMJ*. Jun 15, 2002;324(7351):1434-1437. [doi: [10.1136/bmj.324.7351.1434](https://doi.org/10.1136/bmj.324.7351.1434)] [Medline: [12065269](https://pubmed.ncbi.nlm.nih.gov/12065269/)]
17. Bergmo TS. Can economic evaluation in telemedicine be trusted? A systematic review of the literature. *Cost Eff Resour Alloc*. Oct 24, 2009;7:18. [doi: [10.1186/1478-7547-7-18](https://doi.org/10.1186/1478-7547-7-18)] [Medline: [19852828](https://pubmed.ncbi.nlm.nih.gov/19852828/)]
18. van Steenkiste J, van Dorst P, Dohmen D, Boersma C. Prerequisites for cost-effective home blood pressure telemonitoring: early health economic analysis. *JMIR Cardio*. May 8, 2025;9:e64386. [doi: [10.2196/64386](https://doi.org/10.2196/64386)] [Medline: [40340846](https://pubmed.ncbi.nlm.nih.gov/40340846/)]
19. Boodoo C, Zhang Q, Ross HJ, Alba AC, Laporte A, Seto E. Evaluation of a heart failure telemonitoring program through a microsimulation model: cost-utility analysis. *J Med Internet Res*. Oct 6, 2020;22(10):e18917. [doi: [10.2196/18917](https://doi.org/10.2196/18917)] [Medline: [33021485](https://pubmed.ncbi.nlm.nih.gov/33021485/)]
20. Dansky KH, Palmer L, Shea D, Bowles KH. Cost analysis of telehomecare. *Telemed J E Health*. 2001;7(3):225-232. [doi: [10.1089/153056201316970920](https://doi.org/10.1089/153056201316970920)] [Medline: [11564358](https://pubmed.ncbi.nlm.nih.gov/11564358/)]

21. Noel HC, Vogel DC, Erdos JJ, Cornwall D, Levin F. Home telehealth reduces healthcare costs. *Telemed J E Health*. 2004;10(2):170-183. [doi: [10.1089/tmj.2004.10.170](https://doi.org/10.1089/tmj.2004.10.170)] [Medline: [15319047](https://pubmed.ncbi.nlm.nih.gov/15319047/)]
22. Dixon P, Hollinghurst S, Edwards L, et al. Cost-effectiveness of telehealth for patients with raised cardiovascular disease risk: evidence from the Healthlines randomised controlled trial. *BMJ Open*. Aug 26, 2016;6(8):e012352. [doi: [10.1136/bmjopen-2016-012352](https://doi.org/10.1136/bmjopen-2016-012352)] [Medline: [27566642](https://pubmed.ncbi.nlm.nih.gov/27566642/)]
23. Avery G, Cook D, Talens S. The impact of a telephone-based chronic disease management program on medical expenditures. *Popul Health Manag*. Jun 2016;19(3):156-162. [doi: [10.1089/pop.2015.0049](https://doi.org/10.1089/pop.2015.0049)] [Medline: [26348843](https://pubmed.ncbi.nlm.nih.gov/26348843/)]
24. Henderson C, Knapp M, Fernández JL, et al. Cost effectiveness of telehealth for patients with long term conditions (Whole Systems Demonstrator telehealth questionnaire study): nested economic evaluation in a pragmatic, cluster randomised controlled trial. *BMJ*. Mar 20, 2013;346:f1035. [doi: [10.1136/bmj.f1035](https://doi.org/10.1136/bmj.f1035)] [Medline: [23520339](https://pubmed.ncbi.nlm.nih.gov/23520339/)]
25. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. Mar 29, 2021;372:n71. [doi: [10.1136/bmj.n71](https://doi.org/10.1136/bmj.n71)] [Medline: [33782057](https://pubmed.ncbi.nlm.nih.gov/33782057/)]
26. Lee SW, Chan CK, Chua SS, Chaiyakunapruk N. Comparative effectiveness of telemedicine strategies on type 2 diabetes management: a systematic review and network meta-analysis. *Sci Rep*. Oct 4, 2017;7(1):12680. [doi: [10.1038/s41598-017-12987-z](https://doi.org/10.1038/s41598-017-12987-z)] [Medline: [28978949](https://pubmed.ncbi.nlm.nih.gov/28978949/)]
27. Perednia DA, Allen A. Telemedicine technology and clinical applications. *JAMA*. Feb 8, 1995;273(6):483-488. [Medline: [7837367](https://pubmed.ncbi.nlm.nih.gov/7837367/)]
28. Chong SO, Pedron S, Abdelmalak N, Laxy M, Stephan AJ. An umbrella review of effectiveness and efficacy trials for app-based health interventions. *NPJ Digit Med*. Dec 16, 2023;6(1):233. [doi: [10.1038/s41746-023-00981-x](https://doi.org/10.1038/s41746-023-00981-x)] [Medline: [38104213](https://pubmed.ncbi.nlm.nih.gov/38104213/)]
29. Flacco ME, Manzoli L, Rosso A, et al. Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis. *Lancet Infect Dis*. Apr 2018;18(4):461-472. [doi: [10.1016/S1473-3099\(18\)30048-3](https://doi.org/10.1016/S1473-3099(18)30048-3)] [Medline: [29371070](https://pubmed.ncbi.nlm.nih.gov/29371070/)]
30. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. Oct 18, 2011;343:d5928. [doi: [10.1136/bmj.d5928](https://doi.org/10.1136/bmj.d5928)] [Medline: [22008217](https://pubmed.ncbi.nlm.nih.gov/22008217/)]
31. Paulden M. Calculating and interpreting ICERs and net benefit. *Pharmacoeconomics*. Aug 2020;38(8):785-807. [doi: [10.1007/s40273-020-00914-6](https://doi.org/10.1007/s40273-020-00914-6)] [Medline: [32390067](https://pubmed.ncbi.nlm.nih.gov/32390067/)]
32. Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. *Pharmacoeconomics*. Feb 1996;9(2):113-120. [doi: [10.2165/00019053-199609020-00003](https://doi.org/10.2165/00019053-199609020-00003)] [Medline: [10160090](https://pubmed.ncbi.nlm.nih.gov/10160090/)]
33. Bambha K, Kim WR. Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls. *Eur J Gastroenterol Hepatol*. Jun 2004;16(6):519-526. [doi: [10.1097/00042737-200406000-00003](https://doi.org/10.1097/00042737-200406000-00003)] [Medline: [15167152](https://pubmed.ncbi.nlm.nih.gov/15167152/)]
34. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. Sep 1986;7(3):177-188. [doi: [10.1016/0197-2456\(86\)90046-2](https://doi.org/10.1016/0197-2456(86)90046-2)] [Medline: [3802833](https://pubmed.ncbi.nlm.nih.gov/3802833/)]
35. Manzoli L, Flacco ME, Boccia S, et al. Generic versus brand-name drugs used in cardiovascular diseases. *Eur J Epidemiol*. Apr 2016;31(4):351-368. [doi: [10.1007/s10654-015-0104-8](https://doi.org/10.1007/s10654-015-0104-8)] [Medline: [26620809](https://pubmed.ncbi.nlm.nih.gov/26620809/)]
36. Bang H, Zhao H. Meta-analysis of cost-effectiveness. *Stat Med*. Mar 2026;45(6-7):e70352. [doi: [10.1002/sim.70352](https://doi.org/10.1002/sim.70352)] [Medline: [41850900](https://pubmed.ncbi.nlm.nih.gov/41850900/)]
37. Turner HC, Lauer JA, Tran BX, Teerawattananon Y, Jit M. Adjusting for inflation and currency changes within health economic studies. *Value Health*. Sep 2019;22(9):1026-1032. [doi: [10.1016/j.jval.2019.03.021](https://doi.org/10.1016/j.jval.2019.03.021)] [Medline: [31511179](https://pubmed.ncbi.nlm.nih.gov/31511179/)]
38. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. Sep 6, 2003;327(7414):557-560. [doi: [10.1136/bmj.327.7414.557](https://doi.org/10.1136/bmj.327.7414.557)] [Medline: [12958120](https://pubmed.ncbi.nlm.nih.gov/12958120/)]
39. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editors. *Cochrane Handbook for Systematic Reviews of Interventions Version 6.5*. The Cochrane Collaboration; 2024. URL: <https://www.cochrane.org/authors/handbooks-and-manuals/handbook> [Accessed 2026-07-18]
40. Schechter CB, Cohen HW, Shmukler C, Walker EA. Intervention costs and cost-effectiveness of a successful telephonic intervention to promote diabetes control. *Diabetes Care*. Nov 2012;35(11):2156-2160. [doi: [10.2337/dc12-0048](https://doi.org/10.2337/dc12-0048)] [Medline: [22851599](https://pubmed.ncbi.nlm.nih.gov/22851599/)]
41. Schechter CB, Walker EA, Ortega FM, Chamany S, Silver LD. Costs and effects of a telephonic diabetes self-management support intervention using health educators. *J Diabetes Complications*. Mar 2016;30(2):300-305. [doi: [10.1016/j.jdiacomp.2015.11.017](https://doi.org/10.1016/j.jdiacomp.2015.11.017)] [Medline: [26750743](https://pubmed.ncbi.nlm.nih.gov/26750743/)]
42. Oksman E, Linna M, Hörhammer I, Lammintakanen J, Talja M. Cost-effectiveness analysis for a tele-based health coaching program for chronic disease in primary care. *BMC Health Serv Res*. Feb 15, 2017;17(1):138. [doi: [10.1186/s12913-017-2088-4](https://doi.org/10.1186/s12913-017-2088-4)] [Medline: [28202032](https://pubmed.ncbi.nlm.nih.gov/28202032/)]
43. Islam SM, Peiffer R, Chow CK, et al. Cost-effectiveness of a mobile-phone text messaging intervention on type 2 diabetes—a randomized-controlled trial. *Health Policy Technol*. Mar 2020;9(1):79-85. [doi: [10.1016/j.hlpt.2019.12.003](https://doi.org/10.1016/j.hlpt.2019.12.003)]

44. Palmas W, Shea S, Starren J, et al. Medicare payments, healthcare service use, and telemedicine implementation costs in a randomized trial comparing telemedicine case management with usual care in medically underserved participants with diabetes mellitus (IDEATel). *J Am Med Inform Assoc*. 2010;17(2):196-202. [doi: [10.1136/jamia.2009.002592](https://doi.org/10.1136/jamia.2009.002592)] [Medline: [20190064](https://pubmed.ncbi.nlm.nih.gov/20190064/)]
45. Mason JM, Young RJ, New JP, et al. Economic analysis of a telemedicine intervention to improve glycemic control in patients with diabetes mellitus: illustration of a novel analytic method. *Dis Manag Health Outcomes*. 2006;14(6):377-385. [doi: [10.2165/00115677-200614060-00007](https://doi.org/10.2165/00115677-200614060-00007)]
46. Warren R, Carlisle K, Mihala G, Scuffham PA. Effects of telemonitoring on glycaemic control and healthcare costs in type 2 diabetes: a randomised controlled trial. *J Telemed Telecare*. Oct 2018;24(9):586-595. [doi: [10.1177/1357633X17723943](https://doi.org/10.1177/1357633X17723943)] [Medline: [28814128](https://pubmed.ncbi.nlm.nih.gov/28814128/)]
47. Murray E, Ross J, Pal K, et al. A Web-Based Self-Management Programme for People With Type 2 Diabetes: The HeLP-Diabetes Research Programme Including RCT. NIHR Journals Library; 2018. [doi: [10.3310/pgfar06050](https://doi.org/10.3310/pgfar06050)] [Medline: [30199193](https://pubmed.ncbi.nlm.nih.gov/30199193/)]
48. Tan SH, Ang SB, Tan NC, et al. Cost-effectiveness of a home telemonitoring system for Asian adults with type 2 diabetes mellitus. *Telemed J E Health*. Aug 2024;30(8):2353-2362. [doi: [10.1089/tmj.2024.0143](https://doi.org/10.1089/tmj.2024.0143)] [Medline: [38916871](https://pubmed.ncbi.nlm.nih.gov/38916871/)]
49. Finkelstein EA, Gardner DS, Tham KW, et al. Effectiveness and cost-effectiveness of an app and rewards-based intervention in type 2 diabetes: a randomised controlled trial. *Diabetes Obes Metab*. Feb 2025;27(2):729-739. [doi: [10.1111/dom.16067](https://doi.org/10.1111/dom.16067)] [Medline: [39638769](https://pubmed.ncbi.nlm.nih.gov/39638769/)]
50. Madsen LB, Christiansen T, Kirkegaard P, Pedersen EB. Economic evaluation of home blood pressure telemonitoring: a randomized controlled trial. *Blood Press*. Apr 2011;20(2):117-125. [doi: [10.3109/08037051.2010.532306](https://doi.org/10.3109/08037051.2010.532306)] [Medline: [21105759](https://pubmed.ncbi.nlm.nih.gov/21105759/)]
51. McManus RJ, Mant J, Roalfe A, et al. Targets and self monitoring in hypertension: randomised controlled trial and cost effectiveness analysis. *BMJ*. Sep 3, 2005;331(7515):493. [doi: [10.1136/bmj.38558.393669.E0](https://doi.org/10.1136/bmj.38558.393669.E0)] [Medline: [16115830](https://pubmed.ncbi.nlm.nih.gov/16115830/)]
52. McManus RJ, Little P, Stuart B, et al. HOME and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hypertension: randomised controlled trial. *BMJ*. Jan 19, 2021;372:m4858. [doi: [10.1136/bmj.m4858](https://doi.org/10.1136/bmj.m4858)] [Medline: [33468518](https://pubmed.ncbi.nlm.nih.gov/33468518/)]
53. Billups SJ, Moore LR, Olson KL, Magid DJ. Cost-effectiveness evaluation of a home blood pressure monitoring program. *Am J Manag Care*. Sep 1, 2014;20(9):e380-e387. [Medline: [25364874](https://pubmed.ncbi.nlm.nih.gov/25364874/)]
54. Reed SD, Li Y, Oddone EZ, et al. Economic evaluation of home blood pressure monitoring with or without telephonic behavioral self-management in patients with hypertension. *Am J Hypertens*. Feb 2010;23(2):142-148. [doi: [10.1038/ajh.2009.215](https://doi.org/10.1038/ajh.2009.215)] [Medline: [19927132](https://pubmed.ncbi.nlm.nih.gov/19927132/)]
55. Stoddart A, Hanley J, Wild S, et al. Telemonitoring-based service redesign for the management of uncontrolled hypertension (HITS): cost and cost-effectiveness analysis of a randomised controlled trial. *BMJ Open*. May 28, 2013;3(5):e002681. [doi: [10.1136/bmjopen-2013-002681](https://doi.org/10.1136/bmjopen-2013-002681)] [Medline: [23793650](https://pubmed.ncbi.nlm.nih.gov/23793650/)]
56. Dehmer SP, Maciosek MV, Trower NK, et al. Economic evaluation of the home blood pressure telemonitoring and pharmacist case management to control hypertension (Hyperlink) trial. *J Am Coll Clin Pharm*. Oct 2018;1(1):21-30. [doi: [10.1002/jac5.1001](https://doi.org/10.1002/jac5.1001)] [Medline: [30320302](https://pubmed.ncbi.nlm.nih.gov/30320302/)]
57. Ionov MV, Zhukova OV, Yudina YS, et al. Value-based approach to blood pressure telemonitoring and remote counseling in hypertensive patients. *Blood Press*. Feb 2021;30(1):20-30. [doi: [10.1080/08037051.2020.1813015](https://doi.org/10.1080/08037051.2020.1813015)] [Medline: [32954832](https://pubmed.ncbi.nlm.nih.gov/32954832/)]
58. Ziegler A, Öner A, Quadflieg G, et al. Cost-effectiveness of a telemonitoring programme in patients with cardiovascular diseases compared with standard of care. *Heart*. Oct 12, 2023;109(21):1617-1623. [doi: [10.1136/heartjnl-2023-322518](https://doi.org/10.1136/heartjnl-2023-322518)] [Medline: [37316165](https://pubmed.ncbi.nlm.nih.gov/37316165/)]
59. Teo VH, Teo SH, Burkill SM, et al. Effects of technology-enabled blood pressure monitoring in primary care: a quasi-experimental trial. *J Telemed Telecare*. Jan 2024;30(1):121-130. [doi: [10.1177/1357633X211031780](https://doi.org/10.1177/1357633X211031780)] [Medline: [34328375](https://pubmed.ncbi.nlm.nih.gov/34328375/)]
60. van Keulen HM, Bosmans JE, van Tulder MW, et al. Cost-effectiveness of tailored print communication, telephone motivational interviewing, and a combination of the two: results of an economic evaluation alongside the Vitalum randomized controlled trial. *Int J Behav Nutr Phys Act*. Sep 3, 2010;7:64. [doi: [10.1186/1479-5868-7-64](https://doi.org/10.1186/1479-5868-7-64)] [Medline: [20815869](https://pubmed.ncbi.nlm.nih.gov/20815869/)]
61. Hebert PL, Sisk JE, Wang JJ, et al. Cost-effectiveness of nurse-led disease management for heart failure in an ethnically diverse urban community. *Ann Intern Med*. Oct 21, 2008;149(8):540-548. [doi: [10.7326/0003-4819-149-8-200810210-00006](https://doi.org/10.7326/0003-4819-149-8-200810210-00006)] [Medline: [18936502](https://pubmed.ncbi.nlm.nih.gov/18936502/)]
62. Smith B, Hughes-Cromwick PF, Forkner E, Galbreath AD. Cost-effectiveness of telephonic disease management in heart failure. *Am J Manag Care*. Feb 2008;14(2):106-115. [Medline: [18269306](https://pubmed.ncbi.nlm.nih.gov/18269306/)]

63. Bocchi EA, da Cruz FD, Brandão SM, et al. Cost-effectiveness benefits of a disease management program: the REMADHE trial results. *J Card Fail.* Oct 2018;24(10):627-637. [doi: [10.1016/j.cardfail.2018.04.008](https://doi.org/10.1016/j.cardfail.2018.04.008)] [Medline: [29723595](https://pubmed.ncbi.nlm.nih.gov/29723595/)]
64. Boyne JJ, Van Asselt AD, Gorgels AP, et al. Cost-effectiveness analysis of telemonitoring versus usual care in patients with heart failure: the TEHAF-study. *J Telemed Telecare.* Jul 2013;19(5):242-248. [doi: [10.1177/1357633X13495478](https://doi.org/10.1177/1357633X13495478)] [Medline: [24163233](https://pubmed.ncbi.nlm.nih.gov/24163233/)]
65. González-Guerrero JL, Hernández-Mocholi MA, Ribera-Casado JM, García-Mayolín N, Alonso-Fernández T, Gusi N. Cost-effectiveness of a follow-up program for older patients with heart failure: a randomized controlled trial. *Eur Geriatr Med.* Aug 2018;9(4):523-532. [doi: [10.1007/s41999-018-0074-y](https://doi.org/10.1007/s41999-018-0074-y)] [Medline: [34674493](https://pubmed.ncbi.nlm.nih.gov/34674493/)]
66. Duncan BB, Magliano DJ, Boyko EJ. IDF Diabetes Atlas 11th edition 2025: global prevalence and projections for 2050. *Nephrol Dial Transplant.* Dec 23, 2025;41(1):7-9. [doi: [10.1093/ndt/gfaf177](https://doi.org/10.1093/ndt/gfaf177)] [Medline: [40874767](https://pubmed.ncbi.nlm.nih.gov/40874767/)]
67. Ravi S, Meyerowitz-Katz G, Yung C, et al. Effect of virtual care in type 2 diabetes management - a systematic umbrella review of systematic reviews and meta-analysis. *BMC Health Serv Res.* Mar 6, 2025;25(1):348. [doi: [10.1186/s12913-025-12496-0](https://doi.org/10.1186/s12913-025-12496-0)] [Medline: [40050767](https://pubmed.ncbi.nlm.nih.gov/40050767/)]
68. De Groot J, Wu D, Flynn D, Robertson D, Grant G, Sun J. Efficacy of telemedicine on glycaemic control in patients with type 2 diabetes: a meta-analysis. *World J Diabetes.* Feb 15, 2021;12(2):170-197. [doi: [10.4239/wjd.v12.i2.170](https://doi.org/10.4239/wjd.v12.i2.170)] [Medline: [33594336](https://pubmed.ncbi.nlm.nih.gov/33594336/)]
69. Ramsey SD, Willke RJ, Glick H, et al. Cost-effectiveness analysis alongside clinical trials II-an ISPOR Good Research Practices Task Force report. *Value Health.* Mar 2015;18(2):161-172. [doi: [10.1016/j.jval.2015.02.001](https://doi.org/10.1016/j.jval.2015.02.001)] [Medline: [25773551](https://pubmed.ncbi.nlm.nih.gov/25773551/)]
70. Ben-Assuli O. Cost-effectiveness, use and implementation of telehealth solutions for CHF and COPD: a systematic review using the PRISMA method. *Health Policy Technol.* Jun 2025;14(3):101023. [doi: [10.1016/j.hlpt.2025.101023](https://doi.org/10.1016/j.hlpt.2025.101023)]
71. Le Goff-Pronost M, Bongiovanni-Delarozière I. Economic evaluation of remote patient monitoring and organizational analysis according to patient involvement: a scoping review. *Int J Technol Assess Health Care.* Sep 26, 2023;39(1):e59. [doi: [10.1017/S0266462323002581](https://doi.org/10.1017/S0266462323002581)] [Medline: [37750813](https://pubmed.ncbi.nlm.nih.gov/37750813/)]
72. Hayek MA, Giannouchos T, Lawley M, Kum HC. Economic evaluation of blood pressure monitoring techniques in patients with hypertension: a systematic review. *JAMA Netw Open.* Nov 1, 2023;6(11):e2344372. [doi: [10.1001/jamanetworkopen.2023.44372](https://doi.org/10.1001/jamanetworkopen.2023.44372)] [Medline: [37988078](https://pubmed.ncbi.nlm.nih.gov/37988078/)]
73. Tornvall I, Kenny D, Wubishet BL, Russell A, Menon A, Comans T. Economic evaluations of mHealth interventions for the management of type 2 diabetes: a scoping review. *J Diabetes Sci Technol.* Jan 2025;19(1):179-190. [doi: [10.1177/19322968231183956](https://doi.org/10.1177/19322968231183956)] [Medline: [37395212](https://pubmed.ncbi.nlm.nih.gov/37395212/)]
74. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. *Pharmacoeconomics.* 2008;26(9):733-744. [doi: [10.2165/00019053-200826090-00004](https://doi.org/10.2165/00019053-200826090-00004)] [Medline: [18767894](https://pubmed.ncbi.nlm.nih.gov/18767894/)]
75. Neumann PJ, Kim DD. Cost-effectiveness thresholds used by study authors, 1990-2021. *JAMA.* Apr 18, 2023;329(15):1312-1314. [doi: [10.1001/jama.2023.1792](https://doi.org/10.1001/jama.2023.1792)] [Medline: [37071104](https://pubmed.ncbi.nlm.nih.gov/37071104/)]
76. Sterne JA, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ.* Aug 28, 2019;366:l4898. [doi: [10.1136/bmj.l4898](https://doi.org/10.1136/bmj.l4898)] [Medline: [31462531](https://pubmed.ncbi.nlm.nih.gov/31462531/)]

Abbreviations

HbA_{1c}: hemoglobin A_{1c}

ICER: incremental cost-effectiveness ratio

PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses

QALY: quality-adjusted life year

RCT: randomized controlled trial

SBP: systolic blood pressure

WTP: willingness to pay

Edited by Alexandre Castonguay; peer-reviewed by Piero Giacomelli, Yi Wang; submitted 16.Mar.2026; final revised version received 03.Jul.2026; accepted 06.Jul.2026; published 12.Aug.2026

Please cite as:

Acuti Martellucci C, Gregori N, Taormina S, Diemberger I, Sena B, Ripamonti GM, Odio C, Flacco ME, Colombo AD, Vassallo S, Manzoli L

Cost-Effectiveness of Telemedicine vs Standard Care for the Management of Diabetes Mellitus, Hypertension, and Heart Failure: Meta-Analysis of Randomized Trials

J Med Internet Res 2026;28:e95367

URL: <https://www.jmir.org/2026/1/e95367>
doi: [10.2196/95367](https://doi.org/10.2196/95367)

© Cecilia Acuti Martellucci, Natalia Gregori, Sara Taormina, Igor Diemberger, Barbara Sena, Gaia Matilde Ripamonti, Camillo Odio, Maria Elena Flacco, Asher Daniel Colombo, Salvatore Vassallo, Lamberto Manzoli. Originally published in the Journal of Medical Internet Research (<https://www.jmir.org>), 12.Aug.2026. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research (ISSN 1438-8871), is properly cited. The complete bibliographic information, a link to the original publication on <https://www.jmir.org/>, as well as this copyright and license information must be included.

Search Strategy, Selection Criteria and Methodological Quality

We used a broad definition of telemedicine (or telehealth), including studies that used a variety of platforms for communication and delivery of intervention, including mobile phones (calls, SMS, apps), internet (computer, video conferencing, tablet), and evaluated different strategies: teleeducation, teleconsultation, telementoring, telecase-management, telemonitoring, or hybrid solutions [25, 26, 27]. With telephone support, care is provided and patient data are collected through the telephone (directly or through app), while with telemonitoring, patient parameters are collected remotely and transmitted to the health professional for later assessment, more recently through smartphone apps [24, 28].

Two investigators (C.A.M. and L.M.) independently searched MEDLINE, Scopus, and ClinicalTrials.gov, and the Tufts Medical Center Cost-Effectiveness Analysis (CEA) Registry, using various combinations of the following search terms: "telemedicine OR tele-medicine OR telehealth OR tele-health OR eHealth OR mHealth OR telemetric OR telenursing OR teleeducation OR tele-education OR teleconsultation OR teleconsultation OR telementoring OR tele-mentoring OR telecase-management OR telemonitoring OR telemonitoring" AND "cost-effectiveness OR ICER OR QALY OR cost-utility OR cost-benefit" AND "randomized trial OR RCT OR randomized OR randomized controlled trial OR randomized clinical trial" (last search update June 29 2026). While maintaining a common overall architecture, several alternative strings were used after adjustment for each database [29]. The reference lists of reviews and retrieved articles were also searched, and no language or date restrictions were used. The methodological quality of the included studies was assessed using the revised Cochrane risk-of-bias tool [30]. Discrepancies in the study selection and/or quality assessment were solved by a senior author (L.M.). This study was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [25].

References

24. Henderson C, Knapp M, Fernández JL, Beecham J, Hirani SP, Cartwright M, et al. Cost effectiveness of telehealth for patients with long term conditions (Whole Systems Demonstrator telehealth questionnaire study): nested economic evaluation in a pragmatic, cluster randomised controlled trial. *BMJ*. 2013 Mar 20;346:f1035.
25. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021 Mar 29;372:n71.
26. Lee SWH, Chan CKY, Chua SS, Chaiyakunapruk N. Comparative effectiveness of telemedicine strategies on type 2 diabetes management: A systematic review and network meta-analysis. *Sci Rep*. 2017 Oct 4;7(1):12680.
27. Perednia DA, Allen A. Telemedicine technology and clinical applications. *JAMA*. 1995 Feb 8;273(6):483-8.
28. Chong SOK, Pedron S, Abdelmalak N, Laxy M, Stephan A-J. An umbrella review of effectiveness and efficacy trials for app-based health interventions. *npj Digital Medicine*. 2023 2023/12/16;6(1):233.
29. Flacco ME, Manzoli L, Rosso A, Marzuillo C, Bergamini M, Stefanati A, et al. Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis. *Lancet Infect Dis*. 2018 Apr;18(4):461-72.
30. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011 Oct 18;343:d5928.

Multimedia Appendix 2 Table. RCTs evaluating the cost-effectiveness of Telemedicine versus Standard Care for the management of type II diabetes and hypertension, that estimated an Incremental Cost-Effectiveness Ratio (ICER) value per one clinical outcome.

Study	Year	Country	Intervention	Sample	Follow-up	C.E. Threshold (\$)	Perspective	Outcome 1	Outcome 2	Significance
<u>Type II diabetes</u>								ICER per QALY	ICER per 1% HbA1c (\$)	
Mason [45]	2006	UK	Call-center support	591	12m	59,466 / QALY	Health-care provider	66,800	2500	Not reported
Palmas (IDEATel Trial) [44]	2010	USA	Telemonitoring + PC case management	1665	60m	Not reported	Health-care provider		29,869	Not reported
Schetcher [40]	2012	USA	Telephonic behavioral intervention	526	12m	1000 / 1% HbA1c	Health-care provider		491	Not reported
Schetcher [41]	2016	USA	Telephone self-management support	694	12m	Not reported	Health-care provider		2109	Not reported
Oksman [42]	2017	Finland	Nurse telephone coaching	1570	12m	56,500 / QALY	Health- and social-care system	45,514		Not reported
Warren [46]	2017	Australia	Care coordination via home monitor	126	6m	Not reported	Health-care system		1046	Not reported
Murray B [47]	2018	UK	Web-based tool	374	12m	26,652 to 39,978 / QALY	Health-care system	Dominated control		-
Islam [43]	2020	Bangladesh	Text messaging	236	6m	25,618 / QALY	Health-care system	2406	38	Not reported
Tan [48]	2024	Singapore	Telemonitoring	319	6m	23,408 / QALY	Health-care system	28,648	775	Not reported
Finkelstein [49]	2024	Singapore	Apps and devices	233	12m	Not reported	Health-care system	6531		Not reported
<u>Hypertension</u>								ICER per QALY (\$)	ICER per <1 mmHg SBP (\$)	
McManus [51]	2005	UK	Telemonitoring	441	12m	Not reported	Health-care provider		9	(95% CI: -13 ; 35)
Reed [54]	2010	USA	Telemonitoring	636	24m	Not reported	Health-care system		297	Not reported
Van Keulen ^B [60]	2010	Netherlands	Telephone motivational interviews	1629	18m	27,600 / QALY	Health-care system	Dominated by control		-
Madsen [50]	2011	Denmark	Telemonitoring	223	6m	Not reported	Health-care provider		48	(Uncertainty Interval: -161; 849)
Stoddart [55]	2013	UK	Telemonitoring	401	6m	Not reported	Health-care system		40	(95% CI: 25; 73)
Billups [53]	2014	USA	Telemonitoring	348	6m	Not reported	Health-care provider		21	Not reported
Dehmer [56]	2018	USA	Telemonitoring + Pharmacist	299	12m	Not reported	Health-care provider		139	(Confidence Range: 46; 347)
McManus [52]	2021	UK	Telemonitoring	622	12m	27 to 49 / <1mmHg SBP	Health-care system		15	(95% CI: 8; 39)
Ionov [57]	2021	Russia	Telemonitoring	240	3m	1357 to 4071 / <1mmHg SBP	Health-care provider	4932	13	Not reported
Teo ^A [59]	2021	Singapore	Telemonitoring	240	6m	Not reported	Health-care provider	23,935	469	Not reported
Ziegler [58]	2023	Germany	Telemonitoring	957	12m	15,705 / QALY	Health-care provider	11,527		Not reported
<u>Heart failure</u>										
Hebert [61]	2008	USA	Telephone management	406	12m	25,000 / QALY	Societal	17,543		(95% CI: -139,295; 458,900)
Smith [62]	2008	USA	Telephone management	1069	18m	100,000 / QALY	Health-care system	101,120		(95% CI: 51,345; 315,194)
Boyne [64]	2013	Netherlands	Telemonitoring	382	12m	66,451 / QALY	Health-care system	53,558		Not reported
Bocchi [63]	2018	Brazil	Telephone and face-to-face communication	350	18m	5000 to 25,000 / QALY	Health-care provider	7345		(95% CI: -16,573; +921)
Gonzalez-Guerrero ^B [65]	2018	Spain	Telephone management	117	12m	51,889 / QALY	Health-care system + societal	-38,274 Dominated control		(95% CI: -395,903; 217,935) -
Ziegler [58]	2023	Germany	Telemonitoring	964	12m	15,705 / QALY	Health-care provider	27,286		Not reported

CI: Confidence interval. C.E.: Cost-Effectiveness. QALY: Quality-adjusted Life Year. HbA1c: Glycated hemoglobin. SBP: Systolic blood pressure. ^A Quasi-experimental design. ^B Excluded from the meta-analyses as in a different quadrant of the cost-effectiveness plane.

Multimedia Appendix 3 Table. Quality assessment of the included RCTs, according to the Risk of Bias 2 (RoB2) Tool (Sterne, 2019).

First author	D1 - Randomization process	D2 - Deviations from the intended intervention	D3 - Missing outcome data	D4 - Measurement of the outcome	D5 - Selection of the reported result	Overall
<u>Type II diabetes</u>						
Mason [45]	Some concerns	Some concerns	Some concerns	Some concerns	Low	Some concerns
Palmas (IDEATel Trial) [44]	Some concerns	High	Some concerns	Low	Low	Some concerns
Schetcher 2012 [40]	Some concerns	Some concerns	Some concerns	Low	Low	Some concerns
Schetcher 2016 [41]	Low	Some concerns	Low	Low	Low	Low
Oksman [42]	Some concerns	Low	Some concerns	Some concerns	Low	Some concerns
Warren [46]	Low	Some concerns	High	Low	Low	Some concerns
Murray [47]	Low	Some concerns	Low	Low	Low	Low
Islam [43]	Low	Some concerns	Some concerns	Some concerns	Low	Some concerns
Tan [48]	Some concerns	Some concerns	Some concerns	Low	Low	Some concerns
Finkelstein [49]	Some concerns	Some concerns	Some concerns	Low	Low	Some concerns
<u>Hypertension</u>						
McManus 2005 [51]	Low	Some concerns	Some concerns	Low	Low	Low
Reed [54]	Low	Some concerns	Some concerns	Some concerns	Low	Some concerns
Van Keulen [60]	Low	Some concerns	Some concerns	Some concerns	Low	Some concerns
Madsen [50]	Low	Low	Some concerns	High	Low	Some concerns
Stoddart [55]	Some concerns	Some concerns	High	High	Low	High
Billups [53]	Low	Low	Low	Some concerns	Low	Low
Dehmer [56]	Some concerns	Some concerns	Some concerns	Low	Low	Some concerns
McManus 2020 [52]	Some concerns	Low	Some concerns	Low	Low	Low
Ionov [57]	Low	Low	Some concerns	Some concerns	Some concerns	Some concerns
Teo [59]	High	High	Some concerns	Some concerns	Some concerns	High
Ziegler [58]	Low	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns
<u>Heart failure</u>						
Hebert [61]	Low	Low	Some concerns	Some concerns	Some concerns	Some concerns
Smith [62]	Low	Some concerns	Low	Some concerns	Some concerns	Some concerns
Boyne [64]	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns	Some concerns
Bocchi [63]	Low	Low	Some concerns	Some concerns	Some concerns	Some concerns
Gonzalez-Guerrero [65]	Low	Some concerns	Low	Some concerns	Some concerns	Some concerns
Ziegler [58]	Low	Some concerns	Low	Some concerns	Some concerns	Some concerns

Figure 2. Randomized controlled trials (RCTs) evaluating the cost-effectiveness of telemedicine vs standard care (after 12 months of follow-up) for the management of patients with type 2 diabetes mellitus, hypertension, and heart failure: incremental cost-effectiveness ratio per quality-adjusted life year (QALY) [36,37,39,42,43,51-53,55-58].




Figure 3. Random-effects meta-analysis of the randomized controlled trials (RCTs) evaluating the cost-effectiveness of telemedicine vs standard care for hypertension management: incremental cost-effectiveness ratio needed to achieve a 1-mm Hg reduction in systolic blood pressure [44-46,49,50].





Figure 5. Randomized controlled trials (RCTs) evaluating the cost-effectiveness of telemedicine vs standard care (after 12 months of follow-up) for type 2 diabetes management: incremental cost-effectiveness ratio needed to achieve a 1% reduction in absolute values of haemoglobin A_{1c} [34,35,37-40,42].



PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	Page 1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Page 3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Page 4
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Page 4
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Pages 4,5
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Page 5
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Page 5
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Pages 4,5
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Pages 5,6
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Page 5
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Pages 5,6
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Page 5
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Page 5
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	Page 6
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Page 6
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	Page 6
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	Pages 5,6
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	Page 6
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Page 6
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	Page 6
Certainty	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Page 6

PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
assessment			
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	Page 6, Figure S1
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	Page 6
Study characteristics	17	Cite each included study and present its characteristics.	Pages 6,7, Table 1
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	Page 7, Table S1
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	Pages 7,8
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	Page 7
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	Figures 1,3,4
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Pages 7,8, Figure 2
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Pages 7,8, Figure 5
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Page 7
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	Pages 7,8
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Pages 8,9,10
	23b	Discuss any limitations of the evidence included in the review.	Page 10
	23c	Discuss any limitations of the review processes used.	Page 10
	23d	Discuss implications of the results for practice, policy, and future research.	Pages 8,9,10
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Page 5
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	NA
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	NA
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page 11
Competing interests	26	Declare any competing interests of review authors.	Page 11

Section and Topic	Item #	Checklist item	Location where item is reported
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Data extracted from included studies: Table 1

From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi: 10.1136/bmj.n71. This work is licensed under CC BY 4.0. To view a copy of this license, visit <https://creativecommons.org/licenses/by/4.0/>